Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Adalimumab

3

XVII.b Opportunistic pulmonary/systemic infections

2
Last update : 31/12/2013
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
TNF-alpha antagonists / inhibitors
5

Publications

Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease.
The Journal of pediatrics 2018 Oct;201;166-175.e3 2018 Oct
Miliary tuberculosis following negative latent tuberculosis infection screening prior to tumor necrosis factor-α antagonists: implications for management?
The Journal of rheumatology 2012 Jun;39;1297-8 2012 Jun
Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients.
Modern rheumatology 2012 Aug;22;498-508 2012 Aug
Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.
Current rheumatology reviews 2011 Feb;7;77-87 2011 Feb

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies